© Hamamatsu 2017 Naozoomer D360Hamamatsu: NanoZoomer – digitizing clinical pathology

Hamamatsu Photonics introduces the NanoZoomer S360, a new high throughput Whole Slide Imaging scanner, engineered using Hamamatsu Photonics’ extensive experience of imaging technology and designed to meet the challenging requirements of digitizing routine clinical pathology.

This new high throughput scanner has a capacity of 360 slides (76 mm x 26 mm), features revolutionary scanning technology and delivers fast scanning of 82 slides per hour (at 20x and 40x magnification).

The high throughput, automated scanning and exceptional image quality are tailored to suit the most demanding applications.

The NanoZoomer S360 also has an intelligent slide management feature which uses custom barcode labels. These barcode labels can personalize specific scanning parameters to successfully prioritise and scan different tissues with minimal user-scanner interaction.

Source: Hamamatsu Deutschland 

Back to section

Related Editorial Articles

B2Bioworld offers you background information

Close-up: National Center for Tumor Diseases
An independent and non-sponsored look by B2Bioworld Editors

Opening up Emerging Markets for Rapid Diagnostics and Point-of-Care Assays
David Dolinger shares experience and insight. Do’s and don’ts in developing viable tests for medical, agricultural, or food diagnostics, and bringing these to low resource countries

AstraZeneca and MedImmune Trigger Public Investments into Brazil's Translational Healthcare
A public-private partnership becomes a building block of São Paulo State’s industrial diversification strategy of State

The Myriad Way
Peter D Meldrum, former CEO of the genetics company about battles on patents, cancer chips, and competitors in commercial academia

Printable matrices for bioprinting applications
Short communication by Markus Rimann, bioprinting developer at ZHAW, Wädenswil (CH)

Transition Cancer Research Translation
Christof von Kalle, Head of Germany’s National Center for Tumor Diseases on transitions in translational cancer research

Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only. Their inclusion on B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.